GABAergic and Glutamatergic Deficits in Schizophrenia: Pathophysiological Mechanisms Underlying Negative Symptoms and Cognitive Impairment
International Journal of Molecular Sciences · 17.11.2026 · 27 (22) · 10293
DOI: 10.3390/ijms272210293 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.11.2026. Verfasst von Anna Maria Zakrzewska und 2 weiteren Autor:innen. Die Arbeit nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Schizophrenia is a complex neurodevelopmental disorder characterized by positive, negative, and cognitive symptoms. While classical dopaminergic models explain psychotic features, they fail to address the debilitating negative and cognitive deficits that dictate long-term disability. We aim to synthesize contemporary evidence on the impairment of the excitatory/inhibitory (E/I) balance within cortical microcircuits as a central pathophysiological hypothesis of the disorder. The cascade is hypothesized to be driven by N-methyl-D-aspartate (NMDA) receptor hypofunction, which impairs parvalbumin-positive (PV+) interneurons and consequently downregulates glutamic acid decarboxylase (GAD67)-mediated gamma-aminobutyric acid (GABA) synthesis. Weakened PV+ interneuron function disrupts Pyramidal-Interneuron Network Gamma (PING) dynamics, reducing gamma-band synchronization and fronto-temporo-thalamic connectivity. At the macroscopic and cellular levels, the E/I imbalance is linked to reduced neuropil volume and aberrant synaptic pruning that disturbs dendritic architecture. Clinically, this triggers severe working memory dysfunction, cognitive rigidity, avolition, and anhedonia. This paper presents emerging glutamatergic and GABAergic pharmacological strategies, including glycine, D-serine, and metabotropic glutamate receptor (mGluR) modulators. We highlight key directions for future research, emphasizing the use of translational biomarkers (e.g., mismatch negativity (MMN), magnetic resonance spectroscopy (MRS), and gamma oscillations) to normalize PV+ interneuron function and network-level synchronization.
Zitieren
APA
Zakrzewska, A. M., Gabryelska, A., & Strzelecki, D. (2026). GABAergic and Glutamatergic Deficits in Schizophrenia: Pathophysiological Mechanisms Underlying Negative Symptoms and Cognitive Impairment. International Journal of Molecular Sciences, 27(22), 10293. https://doi.org/10.3390/ijms272210293
Vancouver
Zakrzewska AM, Gabryelska A, Strzelecki D. GABAergic and Glutamatergic Deficits in Schizophrenia: Pathophysiological Mechanisms Underlying Negative Symptoms and Cognitive Impairment. International Journal of Molecular Sciences. 2026;27(22):10293. doi:10.3390/ijms272210293
BibTeX
@article{Zakrzewska2026,
author = {Zakrzewska, Anna Maria and Gabryelska, Agata and Strzelecki, Dominik},
title = {GABAergic and Glutamatergic Deficits in Schizophrenia: Pathophysiological Mechanisms Underlying Negative Symptoms and Cognitive Impairment},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {22},
pages = {10293},
doi = {10.3390/ijms272210293}
}
EUVIMED